Please assess the completion status of the following clinical trial:

Trial Title: Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged from 18 to 65 years.~* Patient with pathologically proven, high grade B-cell Lymphoma CD 20 positive (WHO classification) :~* Diffuse large B cell lymphoma.~* Adverse prognostic factors IPI\>1~* In Complete Remission, or partial response to first line treatment.~* Previously treated with chemotherapy regimen containing rituximab: R CHOP or R ACVBP~* Chemo-sensitive disease~* PET Scan prior transplant~* Eligible for autologous stem cell transplantation~* With a minimum life expectancy of 3 months.~* Negative HIV, HBV and HCV serologies (in the last 4 weeks except after vaccination).~* Having previously signed a written informed consent.~Exclusion Criteria:~* Histological transformation in diffuse large B cell lymphoma, any type of low grade lymphoma~* More than one line of treatment. Prior transplantation. Prior exposure to Zevalin~* Central nervous system or meningeal involvement by lymphoma.~* Contraindication to any drug contained in the chemotherapy regimen.~* Any serious active disease or co-morbid medical condition (according to the investigator's decision and information provided in the IDB).~* Poor renal function (creatinin level up to 2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~* Poor hepatic function (total bilirubin level up to 30 micro mol/l, transaminases up to 2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~* Poor bone marrow reserve as defined by neutrophils less than 1.5 G/l or platelets less than 100 G/l~* Large bone marrow irradiation more than 40percent.~* Bone marrow infiltration~* Lack of sufficient autologous hematopoietic stem cells for transplantation.~* Prior treatment with murine antibodies~* Known hypersensibility to murine antibodies or proteins~* Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.~* Adult patient unable to give informed consent because of intellectual impairment.~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).